Free Trial
NASDAQ:CGEM

Cullinan Therapeutics (CGEM) Stock Price, News & Analysis

Cullinan Therapeutics logo
$5.84 -0.06 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 +0.05 (+0.94%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cullinan Therapeutics Stock (NASDAQ:CGEM)

Advanced

Key Stats

Today's Range
$5.77
$5.95
50-Day Range
$5.75
$8.34
52-Week Range
$5.68
$17.98
Volume
700,970 shs
Average Volume
785,572 shs
Market Capitalization
$344.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00
Consensus Rating
Moderate Buy

Company Overview

Cullinan Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CGEM MarketRank™: 

Cullinan Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 653rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cullinan Therapeutics has a consensus price target of $26.00, representing about 345.2% upside from its current price of $5.84.

  • Amount of Analyst Coverage

    Cullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cullinan Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cullinan Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cullinan Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cullinan Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cullinan Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.03% of the float of Cullinan Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cullinan Therapeutics has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cullinan Therapeutics has recently decreased by 0.96%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cullinan Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cullinan Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.03% of the float of Cullinan Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cullinan Therapeutics has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cullinan Therapeutics has recently decreased by 0.96%, indicating that investor sentiment is improving.
  • Search Interest

    5 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cullinan Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.07% of the stock of Cullinan Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cullinan Therapeutics' insider trading history.
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CGEM Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.tc pixel
Cullinan Therapeutics: Q2 Earnings Snapshot
See More Headlines

CGEM Stock Analysis - Frequently Asked Questions

Cullinan Therapeutics' stock was trading at $12.18 at the beginning of the year. Since then, CGEM stock has decreased by 52.1% and is now trading at $5.84.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its quarterly earnings data on Thursday, August, 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.24.

Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/07/2025
Today
10/06/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGEM
CIK
1789972
Fax
N/A
Employees
30
Year Founded
2016

Price Target and Rating

High Price Target
$32.00
Low Price Target
$22.00
Potential Upside/Downside
+345.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$167.38 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.56%
Return on Assets
-34.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.83
Quick Ratio
9.83

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.14 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
59,070,000
Free Float
55,488,000
Market Cap
$344.97 million
Optionable
Optionable
Beta
-0.12

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CGEM) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners